Synthesis and SAR of piperazine amides as novel c-jun N-terminal kinase (JNK) inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 12, 2009, Pages 3344-3347

  Shin, Youseung ^a   Chen, Weiming ^a   Habel, Jeff ^a   Duckett, Derek ^a   Ling, Yuan Yuan ^a   Koenig, Marcel ^a   He, Yuanjun ^a   Vojkovsky, Tomas ^a   LoGrasso, Philip ^a   Kamenecka, Theodore M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

JNK; Kinase

Indexed keywords

AMIDE; PIPERAZINE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR;

ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; STRUCTURE ACTIVITY RELATION; X RAY DIFFRACTION;

AMIDES; CRYSTALLOGRAPHY, X-RAY; DRUG EVALUATION, PRECLINICAL; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; PIPERAZINES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65949111743     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.03.086     Document Type: Article

References (31)

1. Barr R.K., and Bogoyevitch M.A. Int. J. Biochem. Cell Biol. 33 (2001) 1047
2. Weston C.R., and Davis R.J. Curr. Opin. Cell Biol. 19 (2007) 142
3. Gupta S., Barrett T., Whitmarsh A.J., Cavanagh J., Sluss H., Derijard B., and Davis R.J. EMBO J. 15 (1996) 2760
4. Mohit A.A., Martin J.H., and Miller C.A. Neuron 14 (1995) 67
5. Carboni L., Tacconi S., Carletti R., Bettini E., and Ferraguti F. Neuroscience 80 (1997) 147
6. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., Karin M., and Hotamisligil G.S. Nature 402 (2002) 333
7. Bennet B.L., Satoh Y., and Lewis A.J. Curr. Opin. Pharmacol. 3 (2003) 420
8. Han Z., Chang L., Yamnishi Y., Karin M., and Firestein G.S. Arthritis Rheum. 46 (2002) 818
9. Wong W.S.F. Curr. Opin. Pharmacol. 5 (2005) 264
10. Pelaia G., Cuda G., Vatrella A., Gallelli L., Caraglia M., Marra M., Abbruzzese A., Caputi M., Maselli R., Costanzo F.S., and Marsico S.A. J. Cell. Physiol. 202 (2005) 642
11. Blease K., Lewis A., and Raymon H.K. Expert Opin. Emerging Drugs 8 (2003) 71
12. Zhang H., Shi X., Zhang Q.-J., Hampong M., Paddon H., Wahyuningsih D., and Pelech S. J. Biol. Chem. 277 (2002) 43648
13. Kyriakis J.M., and Avruch J. Physiol. Rev. 81 (2001) 807
14. Zhang G.-Y., and Zhang Q.-G. Expert Opin. Invest. Drugs 14 (2005) 1373
15. Kuan C.-Y., Whitmarsh A.J., Yang D.D., Liao G., Schloemer A.J., Davis R.J., and Rakic P. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 15184
16. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., Leisten J.C., Motiwala A., Pierce S., Satoh Y., Bhagwat S.S., Manning A.M., and Anderson D.W. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 13681
17. Ruckle T., Biamonte M., Grippi-Vallotton T., Arkinstall S., Cambet Y., Camps M., Chabert C., Church D.J., Halazy S., Jiang X., Martinou I., Nichols A., Sauer W., and Gotteland J.-P. J. Med. Chem. 47 (2004) 6921
18. Graczyk P.P., Khan A., Bhatia G.S., Palmer V., Medland D., Numata H., Oinuma H., Catchich J., Dunne A., Ellis M., Smales C., Whitfield J., Neame S.J., Shah B., Wilton D., Morgan L., Patel T., Chung R., Desmond H., Staddon J.M., Sato N., and Inoue A. Bioorg. Med. Chem. Lett. 15 (2005) 4666
19. Gaillard P., Jeanclaude-Etter I., Ardissone V., Arkinstall S., Cambet Y., Camps M., Chaber C., Church D., Cirillo R.A., and Gotteland J.-P. J. Med. Chem. 48 (2005) 4596
20. Swahn B.-M., Huerta F., Kallin E., Malmstrom J., Weigelt T., Viklund J., Womack P., Xue Y., and Phverg L. Bioorg. Med. Chem. Lett. 15 (2005) 5095
21. Stocks M.J., Barber S., Ford R., Leroux F., St-Gally S., Teague S., and Xue Y. Bioorg. Med. Chem. Lett. 15 (2005) 3459
22. Swahn B.-M., Xue Y., Arzel E., Kallin E., Magnus A., Plobeck N., and Viklund J. Bioorg. Med. Chem. Lett. 16 (2006) 1397
23. For the review of reported JNK inhibitors:. LoGrasso P., and Kamenecka T. Mini-Rev. Med. Chem. 8 (2008) 755
24. 50s for JNKs 1 and 3 were determined using HTRF. Briefly, final assay concentrations of JNK1, JNK3, biotinylated-ATF2 and ATP were 0.1 nM, 0.3 nM, 0.4 nM and 1 μM, respectively. In each assay the phosphor-Thr71-ATF-2 product was detected using a Europium-cryptate labeled anti-phospho-Thr71-ATF-2 antibody. Streptavidin-allophycocyanin-XL was used as the acceptor. A 10-point dose-response curve for each compound was generated in duplicate and data was fit to a four parameter logistic.
25. Most compounds containing the bromofuran moiety had microsome stabilities for rat ≤5 min.
26. 50 values were determined using a four parameter logistic and a 10-point dilution curve for each of the inhibitors covering four orders of magnitude of inhibitor concentration.
27. Liu M., Wang S., Clampit J.E., Gum R.J., Haasch D.L., Rondinone C.M., Trevillyan J.M., Abad-Zapatero C., Fry E.H., Sham H.L., and Liu G. Bioorg. Med. Chem. Lett. 17 (2007) 668
28. Alam M., Beevers R.E., Ceska T., Davenport R.J., Dickson K.M., Fortunato M., Gowers L., Haughan A.F., James L.A., Jones M.W., Kinsella N., Lowe C., Meissner J.W.G., Nicolas A., Perry B.G., Phillips D.J., Pitt W.R., Platt A., Ratcliffe A.J., Sharpe A., and Tait L.J. Bioorg. Med. Chem. Lett. 17 (2007) 3463
29. Crystallographic coordinates of JNK3 complexed with 4g have been deposited at the Protein Data Bank (www.rcsb.org/) with PDB ID code 3FV8.
30. Angell R.M., Atkinson F.L., Brown M.J., Chuang T., Christopher J.A., Cichy-Knight M., Dunn A.K., Hightower K.E., Malkakorpi S., Musgrave J.R., Neu M., Rowland P., Shea R.L., Smith J.L., Somers D.O., Thomas S.A., Thompson G., and Wang R. Bioorg. Med. Chem. Lett. 17 (2007) 1296
31. Szczepankiewicz B.G., Kosogof C., Nelson L.T., Liu G., Liu B., Zhao H., Serby M.D., Xin Z., Liu M., Gum R.J., Haasch D.L., Wang S., Clampit J.E., Johnson E.F., Lubben T.H., Stashko M.A., Olejniczak E.T., Sun C., Dorwin S.A., Haskins K., Abad-Zapatero C., Fry E.H., Hutchins C.W., Sham H.L., Rondinone C.M., and Trevillyan J.M. J. Med. Chem. 49 (2006) 3563